Epitope-Specific Immunotherapy Targeting CD4-Positive T Cells in Celiac Disease: Safety, Pharmacokinetics, and Effects on Intestinal Histology and Plasma Cytokines with Escalating Dose Regimens of Nexvax2 in a Randomized, Double-Blind, Placebo-Contr
about
Epitope-Specific Immunotherapy Targeting CD4-Positive T Cells in Celiac Disease: Safety, Pharmacokinetics, and Effects on Intestinal Histology and Plasma Cytokines with Escalating Dose Regimens of Nexvax2 in a Randomized, Double-Blind, Placebo-Contr
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Epitope-Specific Immunotherapy ...... d, Double-Blind, Placebo-Contr
@en
Epitope-Specific Immunotherapy ...... d, Double-Blind, Placebo-Contr
@nl
type
label
Epitope-Specific Immunotherapy ...... d, Double-Blind, Placebo-Contr
@en
Epitope-Specific Immunotherapy ...... d, Double-Blind, Placebo-Contr
@nl
prefLabel
Epitope-Specific Immunotherapy ...... d, Double-Blind, Placebo-Contr
@en
Epitope-Specific Immunotherapy ...... d, Double-Blind, Placebo-Contr
@nl
P2093
P2860
P1433
P1476
Epitope-Specific Immunotherapy ...... d, Double-Blind, Placebo-Contr
@en
P2093
A James M Daveson
Anita Treohan
James A MacDougall
Jane M Andrews
John L Dzuris
Leslie J Williams
Michael P Cooreman
Robert P Anderson
Timothy King
P2860
P356
10.1016/J.EBIOM.2017.11.018
P577
2017-11-22T00:00:00Z